Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II
- Conditions
- Bacterial Keratitis
- Interventions
- First Posted Date
- 2024-02-22
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 60
- Registration Number
- NCT06271772
- Locations
- 🇧🇷
Federal University of São Paulo, São Paulo, Brazil
🇮🇳Aravind Eye Care System, Madurai, Tamil Nadu, India
A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 120
- Registration Number
- NCT06258265
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Shortened Regimen for Drug-susceptible TB in Children
- Conditions
- Tuberculosis, Lymph NodeMycobacterium TuberculosisTuberculosisTuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 860
- Registration Number
- NCT06253715
- Locations
- 🇮🇳
Indian Council of Medical Research - National Institute for Research in Tuberculosis, Chennai, India
🇮🇳Dr. D.Y. Patil Medical College, Hospital and Research Center, Pune, India
🇮🇩Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 31
- Registration Number
- NCT06215521
- Locations
- 🇺🇸
Covance Clinical Research Unit 1341 Mockingbird Lane, Dallas, Texas, United States
🇺🇸Covance Clinical Research Unit 3402 Kinsman Blvd, Madison, Wisconsin, United States
Oral Antibiotic Outpatient Therapy vs. Placebo in the Treatment of Uncomplicated Acute Appendicitis
- Conditions
- Uncomplicated Acute Appendicitis
- Interventions
- Other: Placebo
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Turku University Hospital
- Target Recruit Count
- 498
- Registration Number
- NCT06210269
- Locations
- 🇫🇮
Kuopio University Hospital, Kuopio, Finland
🇫🇮Mikkeli Central Hospital, Mikkeli, Finland
🇫🇮Lahti Central Hospital, Lahti, Finland
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity
- Conditions
- OverweightObesity
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 110
- Registration Number
- NCT06200467
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT06194032
- Locations
- 🇩🇪
Research Site, Berlin, Germany
A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP
- Conditions
- Community-acquired Bacterial Pneumonia
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Zai Lab (Hong Kong), Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06162286
- Locations
- 🇨🇳
The Third Hospital of Changsha/Respiratory and Critical Care Medicine Department, Changsha, China
🇨🇳Kunming First People's Hospital/Respiratory Medicine, Kunming, China
🇨🇳Shanghai Pulmonary Hospital/Respiratory and Critical Care Medicine Department, Shanghai, China
A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects
- Conditions
- Cardiac Repolarization in Healthy Subjects
- Interventions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 35
- Registration Number
- NCT06161220
- Locations
- 🇺🇸
AXIS Clinicals, LLC, Dilworth, Minnesota, United States
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- University College, London
- Target Recruit Count
- 2500
- Registration Number
- NCT06114628
- Locations
- 🇿🇦
TASK Eden, George, South Africa
🇹🇿NIMR Mbeya, Mbeya, Tanzania
🇿🇦TASK Brooklyn, Cape Town, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.